Stockscreener 앱 받기
9.82
2.15%
-0.16
전일 마감가:
$9.98
열려 있는:
$9.99
하루 거래량:
8,000
Relative Volume:
0.12
시가총액:
$123.97M
수익:
-
순이익/손실:
$-8.89M
주가수익비율:
-14.03
EPS:
-0.7
순현금흐름:
$-6.48M
1주 성능:
+4.55%
1개월 성능:
-4.45%
6개월 성능:
-29.90%
1년 성능:
-25.57%
1일 변동 폭
$9.6485
$10.12
1주일 범위
$9.09
$10.86
52주 변동 폭
$8.06
$18.75
그리니치 Stock (GLSI) Company Profile
명칭
Greenwich Lifesciences Inc
전화
203-434-3290
주소
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
GLSI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GLSI
Greenwich Lifesciences Inc
|
9.82 | 123.97M | 0 | -8.89M | -6.48M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.52 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
606.66 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
615.26 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.11 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
250.00 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
그리니치 Stock (GLSI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-09-01 | 개시 | H.C. Wainwright | Buy |
그리니치 주식(GLSI)의 최신 뉴스
HC Wainwright Issues Pessimistic Estimate for GLSI Earnings - Defense World
Greenwich LifeSciences (NASDAQ:GLSI) Price Target Raised to $39.00 at HC Wainwright - Defense World
Greenwich LifeSciences stock target raised to $39 at H.C. Wainwright By Investing.com - Investing.com Canada
H.C. Wainwright Boosts Greenwich LifeSciences (GLSI) Price Target Amid Promising Trial Results | GLSI Stock News - GuruFocus
(GLSI) Proactive Strategies - news.stocktradersdaily.com
Greenwich Lifesciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Greenwich LifeSciences, Inc. SEC 10-K Report - TradingView
Greenwich LifeSciences (GLSI) Expected to Announce Earnings on Monday - Defense World
GREENWICH LIFESCIENCES Earnings Preview: Recent $GLSI Insider Trading, Hedge Fund Activity, and More - Nasdaq
Greenwich Lifesciences Inc expected to post a loss of 21 cents a shareEarnings Preview - TradingView
Greenwich Lifesciences CEO Snehal Patel acquires $32,760 in stock - Investing.com
Greenwich Lifesciences CEO Snehal Patel acquires $32,760 in stock By Investing.com - Investing.com UK
Greenwich LifeSciences CEO Snehal Patel buys $48,015 in common stock By Investing.com - Investing.com Canada
Greenwich LifeSciences CEO Snehal Patel buys $48,015 in common stock - Investing.com Australia
Investigative Agent Elicits Responses in Phase 3 Breast Cancer Trial - Curetoday
Greenwich LifeSciences reports progress on FLAMINGO-01 trial By Investing.com - Investing.com South Africa
GLSI stock touches 52-week low at $9.05 amid market challenges By Investing.com - Investing.com South Africa
GLSI stock touches 52-week low at $9.05 amid market challenges - Investing.com
Greenwich Lifesciences Provides Global Update On Flamingo-01 - marketscreener.com
Greenwich LifeSciences Provides Global Update on FLAMINGO-01 - GlobeNewswire
Greenwich LifeSciences reports progress on FLAMINGO-01 trial - Investing.com
Major Breakthrough: Cancer Prevention Trial Reports Positive Data, Elite Hospitals Join - Stock Titan
Greenwich LifeSciences (GLSI) Shares Surge on Positive Phase 3 D - GuruFocus
Flamingo cancer vaccine in phase III pink, Greenwich time nigh? - BioWorld MedTech
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Greenwich LifeSciences stock rises on cancer shot data (GLSI) - Seeking Alpha
Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial - The Manila Times
Greenwich Lifesciences Announces Positive Immune Response Data From FLAMINGO-01 Phase III Clinical Trial - MarketScreener
Clinical Trial Success: GLSI's Breast Cancer Therapy Shows Promising Results in Expanded Patient Group - Stock Titan
Greenwich LifeSciences (NASDAQ:GLSI) Trading Down 6.7%Time to Sell? - MarketBeat
Recent 15% decline may not have gone down well with Greenwich LifeSciences, Inc. (NASDAQ:GLSI) insiders who've been purchasing recently - simplywall.st
Greenwich LifeSciences Delays Yearly Report Filing - TipRanks
How To Trade (GLSI) - news.stocktradersdaily.com
Greenwich LifeSciences Extends Lock-Up Period for Directors, Officers to March 2026 - MarketScreener
Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026 - GlobeNewswire
Major Insider Confidence Signal: Greenwich LifeSciences Leadership Locks Shares Until 2026 - Stock Titan
HER2-Positive Breast Cancer Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Roche Pharma AG, Dizal Pharma, Greenwich LifeSciences, Ambrx, Alteogen - Barchart
HER2-Positive Breast Cancer Pipeline 2025: Therapies, MOA - openPR.com
GLSI stock touches 52-week low at $10.52 amid market challenges - Investing.com
Greenwich LifeSciences gets DSMB approval to continue late-stage trial of GLSI-100 - MSN
Greenwich LifeSciences Says Preliminary Safety Data for Breast Cancer Therapy Appears Consistent With Prior Trials - Marketscreener.com
Greenwich LifeSciences reports positive safety data on GLSI-100 - Investing.com India
Greenwich LifeSciences reports positive safety data on GLSI-100 By Investing.com - Investing.com UK
Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01 - GlobeNewswire
Trading (GLSI) With Integrated Risk Controls - news.stocktradersdaily.com
Non-Small Cell Lung Cancer Clinical Trial Pipeline | 100+ Companies Pioneering the Future of Treatment - openPR
55% of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) is owned by insiders, and they've been buying recently - Yahoo Finance
Learn to Evaluate (GLSI) using the Charts - news.stocktradersdaily.com
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Sees Large Increase in Short Interest - MarketBeat
Short Interest in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Increases By 5.1% - MarketBeat
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Verra Mobility Corporation (NASDAQ: VRRM) - PR Newswire
그리니치 (GLSI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.63%
자본화:
|
볼륨(24시간):